Other patients have been in similar situations, with COVID-19 and preexisting complement dysfunctions such as nonsense Factor H, CD46, and PIG-A mutations, and gain of function C3 mutations contributing to acute thrombotic microangiopathy (TMA) [78–81]. Here, C3 is linked to COVID-19.